The primary purpose of any Expanded Access (EAP) or Post-Trial Access (PTA) Program is to help patients with serious or life-threatening conditions gain access to potentially life-saving therapies when no suitable treatment options are available. [...]
Clinical trials are moving out of hospitals and research centers and into people's living rooms. Home visits, remote assessments, and community-based care are no longer a workaround for hard-to-reach patients. They are becoming a core [...]
WEP CLINICAL ANNOUNCES NEW LONDON OFFICE AT CHISWICK BUSINESS PARK WEP Clinical, a global Clinical Research Organization (CRO) supporting biopharmaceutical partners across the full drug development lifecycle, is pleased to announce the opening of its [...]
WEP CLINICAL JOINS THE OLIVER PATCH PROJECT TO CHAMPION CHILDREN FACING SERIOUS ILLNESS THROUGH NATIONAL PATCH DAY WEP Clinical (WEP), a full-service clinical research organization (CRO), today announced its sponsorship of National Patch Day through the Oliver [...]
The first EU Joint Clinical Assessment (JCA) is now published, marking a pivotal new milestone for both the pharmaceutical industry and Healthcare Authorities in Europe.Looking at the first report (tovorafenib in pediatric low‑grade glioma), one [...]
Hybrid and decentralized clinical trial models are often discussed in terms of technology: remote visits, telemedicine, wearable devices, home-based assessments, and digital data collection. While these capabilities are important, they only tell part of the [...]
A WEP Clinical White PaperWith Every Patient Executive Summary Cell and gene therapy (CGT) trials operate at the intersection of scientific precision and operational complexity. These programs require highly controlled environments to ensure product integrity, [...]
Neurology is one of the most dynamic and scientifically promising therapeutic areas in clinical research today. With advances in treatments for Alzheimer’s disease, Parkinson’s, multiple sclerosis, ALS, and rare neurodegenerative disorders moving at an unprecedented [...]
Most site activation delays aren’t caused by complexity. They are caused by how we manage the complexity.In a recent article, WEP’s SVP, Head of Global Project Management, Jen Banks, outlined five key strategies to reduce [...]
At last year’s Operationalize Expanded Access Programs Summit, I explored a question that was on many Sponsors’ minds: "What is the value of collecting real world data in EAPs, and how can it support commercial [...]
